ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletionQuartr·Nov 9, 2026 at 01:05 PMALLO+1.41%
Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trialPUBT·Nov 9, 2026 at 01:04 PMALLO+1.41%
Allogene Therapeutics tumbles 8% as Q3 revenue hits zeroMarket Movers·Nov 6, 2026 at 03:39 PMALLO+1.41%
Allogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q SummaryTradingView·Nov 6, 2026 at 11:01 AMALLO+1.41%
Allogene Therapeutics | 8-K: FY2026 Q3 Revenue: USD 0Earnings Watch·Nov 5, 2026 at 10:13 PMALLO+1.41%
Allogene Highlights CAR T Clinical Progress in Kidney Cancer at SITC MeetingPUBT·Nov 3, 2026 at 01:06 PMALLO+1.41%
